Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vall d'Hebron Institute of Oncology
With
Prostate Cancer Foundation
Instituto de Salud Carlos III
Hospital Vall d'Hebron
Fundacio Puigvert
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Men 18 or over years old.
Patients with castration resistant prostate cancer.
Evidence of bone metastases by any imaging technique.
Patients due to start treatment with abiraterone or enzalutamide. In the exploratory cohorts, we will include patients due to start treatment with other systemic therapies for advanced prostate cancer (A-taxanes, B-radiopharmaceuticals, C-other therapies).
Written (signed and dated) informed consent.
You may not be if
Contraindications to MRI.
Inability of patient to tolerate whole body MRI (e.g. claustrophobia).
Patients who have received radiotherapy within the last three months and with no bone metastases outside the radiotherapy field.
Clareo Health | Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer
